FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News

Mallinckrodt Pays $260 Million on False Claims Violations

Mallinckrodt agrees to pay $260 million to resolve allegations that it violated the False Claims Act by knowingly underpaying Medicaid rebates due for...

Human Drugs

FDA Denies 2013 Anticholinergic Label Petition

FDA denies a petition seeking a stronger Warning on labeling of OTC drugs with anticholinergic effects.

Human Drugs

3 More Comments on RWD Draft Guidance

Three more drug companies comment on an FDA draft guidance on using real-world evidence and data in regulatory decision-making for drugs and biologics...

Human Drugs

Revance Re-files BLA for DaxibotulinumtoxinA

Revance Therapeutics refiles its BLA for DaxibotulinumtoxinA for Injection, indicated for treating moderate to severe glabellar lines, in response to ...

Medical Devices

QS, MDR Issues at Chinas Wickimed

FDA warns Chinas Wickimed Medical Equipment Manufacturing Company about Quality System and Medical Device Reporting violations in its manufacture of s...

Human Drugs

Priority Review for Tibsovo Supplemental NDA

FDA accepts for priority review a Servier supplemental NDA for Tibsovo (ivosidenib tablets) as a potential treatment for patients with previously untr...

Federal Register

FDA Updates Covid-19 Guidance Listing

Federal Register notice: FDA updates is listing of guidance documents related to the Covid19 public health emergency.

Federal Register

2 EUAs Revoked on Covid-19 Tests

Federal Register notice: FDA revokes the Emergency Use Authorizations (EUAs) issued to Bio-Rad Laboratories for the BioPlex 2200SARSCoV2 IgG, and Quot...

Human Drugs

Gileads Mixed Data on Trodelvy in Metastatic Breast Cancer

A Phase 3 study evaluating Gileads Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2-metastatic breast cancer shows that the therapy met...

Human Drugs

FDA Partial Hold on Alpine Immune Cancer Trial

FDA places a partial clinical hold on an Alpine Immune Sciences trial evaluating davoceticept in combination with pembrolizumab (Mercks Keytruda) in a...